In the realm of healthcare, few topics spark as much excitement and skepticism as the potential of weight-loss drugs to prevent cancer. The recent buzz surrounding GLP-1 drugs and their purported cancer-preventive properties has captured the public's imagination, with headlines touting their potential benefits. However, as a clinical epidemiologist, I find myself compelled to offer a nuanced perspective on this emerging narrative, one that navigates the fine line between optimism and caution. What makes this issue particularly fascinating is the interplay between scientific evidence and public perception, where the line between fact and fiction can be remarkably thin.
Cancer, a complex and multifaceted disease, presents a unique challenge for researchers. Unlike a single, homogenous entity, cancer encompasses over a hundred distinct types, each with its own unique biology and risk factors. Breast cancer, lung cancer, and blood cancers are not mere variations of the same disease; they are distinct entities with their own genetic, environmental, and behavioral risks. This diversity makes it incredibly difficult to study the impact of a single drug on cancer, as the results can vary widely across different cancer types.
Before the current buzz surrounding GLP-1 drugs and cancer prevention, there was concern that these drugs might actually increase cancer risk. Researchers initially focused on thyroid cancer, finding that Ozempic, a GLP-1 drug, caused thyroid C-cell tumours in rodents. This led to a black box warning from US regulators in June 2026, advising against its use among those with a personal or family history of thyroid-related conditions. However, it's crucial to note that rodents are not people, and human thyroid C cells are less sensitive to GLP-1 drugs compared to rodent C cells due to differences in GLP-1 receptor expression.
Long-term studies in monkeys did not replicate the abnormal thyroid cell growth seen in rodents, and a 2025 analysis of data from 93 clinical trials found no clear link between taking certain GLP-1 drugs and thyroid cancer. European regulators reached the same conclusion in 2023 after reviewing available research on GLP-1s. Similarly, concerns about pancreatic cancer were also addressed in a 2025 analysis of data from 62 studies, which found no consistent increased risk from taking GLP-1 drugs.
The reassurance is real, but it's essential to recognize that these findings are preliminary. GLP-1 drugs are relatively new, and cancer can take decades to develop. The cancer story, once framed as a potential risk, has now been turned on its head as researchers explore the possibility of GLP-1 drugs preventing or even treating cancer.
A 2024 study of over 1.6 million people with Type 2 diabetes found lower rates of 10 out of 13 obesity-related cancers in those treated with a GLP-1 drug compared to insulin. Another 2025 study of about 87,000 adults found that overall cancer rates among those who started a GLP-1 drug were roughly 17% lower, with the clearest reductions in endometrial and ovarian cancers, as well as a type of brain cancer called meningioma. While the risk of kidney cancer was 38% higher among patients taking GLP-1 drugs, larger studies are needed to confirm its significance.
A 2026 study of over 110,000 women undergoing breast imaging found a roughly 30% lower risk of breast cancer among those who use GLP-1 drugs compared to those who do not. Researchers are also investigating how GLP-1 drugs affect cancer survival rates, with a 2024 study reporting a 34% lower risk of death across six cancer types for those taking GLP-1 drugs.
However, these findings are not without caveats. Studies on the effects of GLP-1 drugs on cancer risk have three key features that make them susceptible to misinterpretation. The first is healthy user bias, where individuals who start a GLP-1 drug tend to be healthier and wealthier than those who do not. This bias is challenging to eliminate in observational studies, which compare people as they are treated in real-life settings rather than randomly assigning the drug.
The second issue is the choice of comparison drug. To understand the effect of a drug, it must be measured against something else. The comparison drug can significantly influence the results of the study. For instance, the 2024 study reported large reductions in cancer risk compared to insulin, but when compared to metformin, a diabetes drug, no clear reduction in cancer risk was observed.
Insulin is reserved for patients with more advanced diabetes, a condition that is itself a risk factor for cancer. In these studies, patients on insulin start with a higher risk of cancer, making it appear protective when measured against a group at higher risk. The apparent benefit came from the comparison drug, not the GLP-1 drug itself.
The third issue is timing. Cancer can take decades to develop, yet most GLP-1 studies follow people for only a handful of years. The apparent cancer benefits of GLP-1 drugs show almost immediately, but prevention doesn't work that quickly. A drug that truly lowers the risk of developing cancer would show its effect gradually as fewer tumours surface over time, not within the first few months of taking the drug.
When cancer risk appears to drop almost as soon as a patient starts treatment, it's a telltale sign that people who start these drugs were already at lower cancer risk, and the GLP-1 drugs are getting credit for that preexisting advantage. Moreover, almost all of this research comes from a handful of high-income countries, even as uptake of these drugs is increasing globally and the burden of cancer disproportionately grows in lower-income countries.
The cleanest way to address these study biases is through randomized trials, which by design make comparison groups alike from the start. Available clinical trials tell a quieter story than the headlines. Two 2025 meta-analyses found little evidence that GLP-1 drugs either raise or lower cancer risk. These meta-analyses are generally more reliable than observational studies because their total amount of data increases their statistical power.
Despite their strengths, these analyses inherit the limitations of the trials they include. Most of the trials in these 2025 studies had a short follow-up of a year or two and recorded too few cancer cases to settle the question. Randomized clinical trials designed to answer the question of whether GLP-1 drugs affect cancer risk would need to enrol tens of thousands of people and follow them for many years.
Until then, the idea that GLP-1 drugs lower cancer risk is a hypothesis worth testing but not a conclusion to act on. The bottom line is that, based on the available evidence, GLP-1 drugs do not appear to raise overall cancer risk. However, more ambitious claims that GLP-1s actively prevent cancer or improve survival after diagnosis remain unproven. If GLP-1s do have an effect on cancer risk, researchers still wouldn't know where that effect comes from: weight loss itself, broader improvement in metabolic function, or a more direct effect on inflammation, the immune system, or tumours.
In conclusion, while the potential of GLP-1 drugs to prevent cancer is intriguing, it's essential to approach this narrative with a critical eye. The available evidence is promising but preliminary, and further research is needed to fully understand the role of GLP-1 drugs in cancer prevention. As a clinical epidemiologist, I believe that while the headlines may be captivating, the science behind them is still evolving, and the story is far from over.
)
